Would you consider amivantamab or datopotamab in a patient with EGFR exon 19 positive metastatic NSCLC adenocarcinoma that progressed on osimertinib, carboplatin, and pemetrexed with biopsy proven transformation to squamous cell carcinoma?
EGFR exon 19 deletion is still detected in the tumor and peripheral blood.